Colombia vs New Zealand: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Colombia
89.0%
in 2025
New Zealand
89.0%
in 2025
Colombia rank
72nd
New Zealand rank
72nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Colombia
- New Zealand
How they compare
Colombia currently reports 89.0% against 89.0% in New Zealand, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was New Zealand ahead.
Colombia ranks 72nd and New Zealand ranks 72nd of 194 countries.
Across the 3 decades both report, Colombia averaged higher in 1 and New Zealand in 2.
Head to head by decade
| Decade | Colombia | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 43.5% | 43.5% | New Zealand |
| 2010s | 78.6% | 92.6% | 14.0% | New Zealand |
| 2020s | 88.0% | 82.5% | 5.5% | Colombia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Colombia or New Zealand?
- Colombia, at 89.0% against 89.0% in New Zealand as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Colombia and New Zealand?
- 0.0%, with Colombia ahead.
- How many years of comparable data are there for Colombia and New Zealand?
- 18 years are reported by both, from 2008 to 2025.
- How do Colombia and New Zealand rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Colombia ranks 72nd and New Zealand ranks 72nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.